Alzheimer's disease is usually described as a two-front war inside the brain: sticky amyloid-beta plaques on one side, tangled clumps of tau protein on the other. For decades, most research attention chasing a single protective molecule capable of holding back both fronts has come up short. A team at Sanford Burnham Prebys in La Jolla, California, just found a protein that appears to fight on both sides at once, and their results, published July 17, 2026, in the journal Science Advances, give the tau side of that battle a genuinely new lead.

A protein already known for half the job

The protein in question is called SORLA, short for sorting-related receptor with A-type repeats. It has been on researchers' radar for 15 to 20 years already, but almost entirely for one specific reason: prior work from the Sanford Burnham Prebys lab and others had established that SORLA can suppress amyloid-beta generation and accumulation, the plaque-forming half of Alzheimer's pathology. What remained far less understood, according to senior author Timothy Huang, PhD, an assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys, was whether SORLA had any effect at all on tau, the disease's other defining culprit.

Tau's job under normal conditions is almost entirely structural. It stabilizes microtubules, the scaffolding filaments that hold a neuron's internal shape and support the networks neurons form with each other. In Alzheimer's disease and a broader family of conditions called tauopathies, tau proteins stop doing that job and instead clump together inside nerve cells, forming toxic tangles linked directly to cognitive decline and neuron death.

How the experiment was built

To test SORLA's effect on tau specifically, Huang's team, led by first author Huijie Huang, PhD, crossbred two engineered mouse lines. One line was already prone to developing tau tangles, brain atrophy, and cognitive deficits, mimicking the progression seen in human tauopathies. The other line was engineered to overproduce human SORLA protein. Crossing the two produced a new mouse model that let researchers directly observe what happens to tau pathology when SORLA levels run higher than normal, and, in a parallel set of experiments, what happens when the Sorl1 gene that produces SORLA is removed entirely.

What extra SORLA actually changed

The results split cleanly in both directions. Mice engineered to overproduce human SORLA showed measurably less tau hyperphosphorylation, the process by which too many phosphate groups get added to tau protein and trigger its transformation into tangle-forming clumps. They also had fewer tau "seeds," the small aggregates that recruit additional tau molecules into ever-larger tangles, along with less overall brain atrophy and healthier, better-preserved synaptic connections between neurons.

Mice lacking the Sorl1 gene entirely showed the opposite pattern: more severe tau damage across the same set of measures. "When you upregulate SORLA, you can suppress the negative effects found in tauopathies," Huijie Huang said, describing a dose-dependent relationship between SORLA levels and the severity of tau pathology that held consistently across the study's various measurements.

The damage extends beyond neurons themselves

Using advanced sequencing techniques, the research team also traced SORLA's protective effects into supporting glial cells, the brain's non-neuronal support cells that play an active role in neurodegenerative disease progression rather than sitting passively on the sidelines. Higher SORLA levels were associated with reduced activation of disease-associated glial gene programs, patterns of gene activity in glial cells that typically ramp up alongside worsening neurodegeneration. That finding matters because it suggests SORLA's protective reach extends beyond simply propping up neurons directly, touching the broader cellular environment that shapes how quickly tau pathology spreads and how much damage it ultimately causes.

A dual-action target, with one important caveat

Because SORLA already had a known role suppressing amyloid-beta and now shows a parallel protective effect against tau, the protein has become a genuinely rare kind of drug target, one capable of addressing both of Alzheimer's defining hallmarks through a single mechanism rather than requiring two separate interventions. Given that Alzheimer's disease affects more than 6 million Americans and tau tangle burden correlates closely with the severity of cognitive decline, a therapy capable of boosting SORLA's natural activity could represent a meaningfully different approach from existing treatments that target amyloid or tau in isolation.

Huang was careful to flag a complication that any future drug development effort will need to navigate. SORLA appears to interact with oncogenic pathways involving genes such as HER2, meaning that simply cranking up SORLA expression to fight neurodegeneration could carry unintended cancer-related risks. Because of that, Huang said the team is now working to find ways to recapitulate SORLA's protective effects without necessarily increasing SORLA expression itself, an approach that would aim to isolate the beneficial downstream mechanisms from the protein's broader biological footprint.

Why this finding matters right now

The Alzheimer's drug pipeline has spent much of the past decade concentrated heavily on amyloid-clearing antibodies, treatments that have shown modest clinical benefit while carrying real safety tradeoffs and high costs. A protein-based approach capable of addressing tau pathology alongside amyloid, through a single well-characterized molecular target with two decades of prior research behind it, offers a different kind of foundation to build from, one grounded in biology researchers already partially understand rather than an entirely novel mechanism starting from zero.

The Sanford Burnham Prebys team's next objective is translating this mouse-model finding into a strategy that could plausibly reach human trials, threading the needle between activating SORLA's neuroprotective functions and avoiding its oncogenic side effects. That work remains in early stages, but the underlying signal, a single protein meaningfully slowing damage on both fronts of Alzheimer's pathology, is the kind of result that tends to justify the years of further research required to turn it into an actual treatment.

---

*Sources cited in this article include the peer-reviewed study published July 17, 2026, in Science Advances, and reporting from ScienceDaily, EurekAlert, MedicalXpress, Newsweek, and Medical Daily covering research from Sanford Burnham Prebys. All figures reflect reporting available as of July 25, 2026.*